BTX News and Press, Brooklyn ImmunoTherapeutics Inc. From 06/02/21

BriaCell Therapeutics (BCTX) +102% after update on the overall survival data of advanced breast cancer patients.Constellation Pharmaceuticals (CNST) +67% on merger agreement with MorphoSys.Stealth BioTherapeutics (MITO) +46% on EMA orphan drug status for elamipretide.AC Immune ...

BROOKLYN, N.Y., June 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and m...

Replay of Presentation is Now Available on the Company’s Website Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treati...

Larimar Therapeutics (LRMR) -40% after FDA puts clinical hold on CTI-1601 program.GSX Techedu (GOTU) -15% after Q1 earnings releaseCarLotz (LOTZ) -16% after losing key sourcing partner temporarily.Travere Therapeutics (TVTX) -13% on sparsentan developme...

Brooklyn Therapeutics' (BTX) exclusive license for mRNA gene editing and cell therapies technology, combined with a desire to form additional partnership, will help drive value and grow the company in the future, according to CEO Howard Federoff.Speaking during an after-the-bell conference ca...

Small-cap stock Brooklyn ImmunoTherapeutics ([[BTX]] -13.8%) has shed more than a tenth of value so far. The company has scheduled a corporate update at 4:30 PM EST today.A 13G filing submitted by Brooklyn ImmunoTherapeutics yesterday indicates an ownership position of ~11.4% h...

Brooklyn ImmunoTherapeutics ([[BTX]] +20.1%) has completed a $20M financing which it said would be used for the development of the mRNA gene editing and cell therapies technology licensed from Factor Biosciences and Novellus Therapeutics.The company expects to use the funds to begin tran...

Brooklyn ImmunoTherapeutics (BTX) announces the appointment of Michael Andreeff to the company's scientific advisory board, effective May 21, 2021.Andreeff currently serves as a Professor of Medicine at MD Anderson Cancer Center where he holds the Paul and Mary H...

Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced the appointment of Michael Andre...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s fair to say that there’s change afoot at Brooklyn Immunotherapeutics (NYSEAMERICAN: BTX ). Some folks are averse to big changes, but BTX stock holders shouldn’t be worried at all. Source:...